CSL Ltd Annual Report 2019

CSL Limited Annual Report 2019 95 Note 1: Segment Information and Business Combinations continued CSL Behring US$m Seqirus US$m Intersegment Elimination US$m Consolidated Entity US$m 2019 2018 2019 2018 2019 2018 2019 2018 Segment assets 11,249.7 10,643.9 1,333.5 1,567.8 (268.8) (1,437.2) 12,314.4 10,774.5 Segment liabilities 6,697.3 6,532.7 634.6 1,599.1 (268.8) (1,437.2) 7,063.1 6,694.6 Other Information – capital expenditure excluding Business Acquisition Payments for property, plant and equipment 1,017.0 732.0 100.6 46.8 – – 1,117.6 778.8 Payments for intangibles 142.1 124.6 25.1 89.2 – – 167.2 213.8 Total capital expenditures excluding Business Acquisition 1,284.8 992.6 Inter-segment sales Inter-segment sales are carried out on an arm’s length basis and reflect current market prices. Geographical areas of operation The Group operates predominantly in Australia, the USA, Germany, the United Kingdom, Switzerland and China. The rest of the Group’s operations are spread across many countries and are collectively disclosed as ‘Rest of World’. Geographic areas Australia US$m United States US$m Germany US$m UK US$m Switzerland US$m China US$m Rest of world US$m Total US$m 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 External Operating Revenue 702.2 691.5 3,973.9 3,521.8 763.9 817.7 510.4 362.6 216.0 227.4 625.8 589.8 1,746.4 1,704.5 8,538.6 7,915.3 Property, plant, equipment and intangible assets 840.0 776.9 2,159.5 1,702.5 737.1 589.3 333.0 321.8 1,804.0 1,487.2 472.3 467.0 16.7 9.2 6,362.6 5,353.9 Note 1b: Business Combination Three business combinations occurred in the financial year ended 30 June 2018. Ruide Acquisition On 1 August 2017 CSL acquired 80% of the equity of Ruide fromHumanwell for US$352m. Ruide develops, manufactures and commercialises plasma-derived products for the Chinese domestic market and provides a vehicle for the Group to access this growing market for plasma therapeutics. On 20 June 2018, Humanwell and CSL renegotiated the terms and conditions under which the remaining consideration would be paid. The payment of $102m for the 20% equity initially retained by Humanwell was paid in June 2018. There was no change to the acquisition accounting disclosed in the annual financial report of CSL Limited as at 30 June 2018. Calimmune Acquisition On 31 August 2017 CSL acquired 100% of the equity of Calimmune Inc for an upfront payment of $82m and a series of contingent payments subject to the achievement of development milestones. Calimmune has developed a suite of gene therapy technologies that may prove the basis of treatments for rare diseases. The acquisition provides CSL with a new technology platform and manufacturing process. There was no change to the acquisition accounting disclosed in the annual financial report of CSL Limited as at 30 June 2018. Guangzhou Junxin Pharmaceutical Acquisition On 14 May 2018 CSL acquired 100% of the equity of Guangzhou Junxin Pharmaceutical Limited. The acquired entity holds a GSP (Good Supply Practice) licence granted by the Chinese regulator. This licence enables the holder to own and sell inventory in the domestic Chinese market. In the future CSL will be able to participate more fully in the value chain for Albumin imported into China. This entity will also sell Ruide manufactured product in China. There was no change to the acquisition accounting disclosed in the annual financial report of CSL Limited as at 30 June 2018.